The Entire Product Is Available: Fill & Download for Free

The Osborne Computer Corporation pioneered in portable computers. They developed the world's first portable computer in 1981.The Osborne 15 inch (127 mm) 52-column displaytwo floppy-disk drivesa Z80 microprocessor64 KB of RAMcould fit under an airplane seatcould survive being accidentally droppedincluded a bundled software package that included the CP/M operating system, the BASIC programming language, the WordStar word processing package, and the SuperCalc spreadsheet programOsborne Computer Corporation's first product was ready soon after its founding! The peak sales per month for it over the course of the product lifetime was 10,000 units, despite the initial business plan for the computer predicting a total of only 10,000 units sold over the entire product lifecycle.The companies’ biggest mistake was introducing the next model, Osborne Executive, too soon. Adam Osborne damaged his company's current sales when he began showing the Executive to journalists in early 1983.Dealers rapidly started cancelling orders for the Osborne 1 in anticipation of the new Executive.The Osborne effect is a term referring to the unintended consequences of a company pre-announcement made either unaware of the risks involved or when the timing is misjudged, which ends up having a negative impact on the sales of the current product. This is often the case when a product is announced too long before its actual availability. This has the immediate effect of customers canceling or deferring orders for the current product, knowing that it will soon be obsolete, and any unexpected delays often means the new product comes to be perceived as vaporware, damaging the company's credibility and profitability.The term was coined after the Osborne Computer Corporation, in which the company took more than a year to make its next product available and eventually ran out of cash and went bankrupt in 1985

GST implementation.Sure, the start was painful, fucked up almost totally but it's excellent now.I owned 4 factories all over India, the other 3 were just assembling lines, the major production occured in the fourth, largest factory in Maharashtra. Skilled, attending everyday labour wasn't available in Karnataka, Jharkhand, or in Punjab.But to escape VAT and all the related shitshow associated with it, I had to operate 4 factories.With GST I've closed down the other 3, and that caused a loss of about 9500 jobs. On the other hand, I've been able to utilise the entire ~5000 square metres of factory space in Maharashtra. I've actually hired 12000 more people. That's a net increase of 2500 jobs. About 50% of them are filled by labourers from the shut down factories.My transportation costs have decreased, my accounting staff is down from 23 to 7, administration overhead is at a mere 7% from a previous high of 22%, and tax filings have become so much easier.My production costs are lower by about 8.5%, and the labourers at the lowest part in wages, have had an increase of 10% in their wages.This is not only my experience but also others.Production is getting efficient, on a larger scale, shit is getting cheaper, and benefits have already been passed on. FMCG shit has become cheaper, those who don't pass on benefits pay fines.Now, it's possible for companies and individuals to set up large plants in India, and not be burdened by a very horrendous tax regime.

There are two vaccines available in quantity in the EU and UK at this time - the Oxford/AstraZeneca and BioNTech/Pfizer vaccines.The BioNTech/Pfizer mRNA vaccine, which is made by a predominantly chemical process is produced in only one plant in the world outside of the USA - Puurs in Belgium. That plant is contracted by Pfizer to supply the entire world outside of the US with the BioNTech vaccine.The Oxford/AstraZeneca genetically modified virus vaccine is made by what can loosely be termed a fermentation process and as it uses live material throughout is not as consistent in manufacture as the BioNTech vaccine. Like all such full virus vaccines, production needs to be ramped up as experience is gained with the process.Listening to Mairead McGuinness, an EU Trade Commissioner, talking this morning about the EU’s approach to vaccine exports, she stated that the EU had been ‘international not national’ in its approach. This was, at best, a half truth - the Pfizer plant is contracted to supply the whole world outside the US - it is its sole purpose.It is not some act of beneficence by the EU, but a contractual obligation by the plant’s owner, Pfizer.So, leaving that aside, which amounts to a high 90%+ of the 41 million doses exported that she was talking about, we are left with AstraZeneca and the Oxford vaccine.Prior to 2020 AZ had never made a vaccine before - this was their first attempt at such a procedure. They would have been much better off making the BioNTech vaccine, which better matched their skill set, but they built up the plant in the UK to actually produce the material - with a lot of financial support from the UK Government - and, after initial delays, are now working at full speed.They did not have the same advantages in continental Europe, where the order was late coming in and the same degree of assistance was not provided in establishing plant. As a result, AZ has been unusually dependent on third parties to get the job done, and that’s where most of the problems have occurred.At the same time, the Oxford vaccine has been licensed around the world and the Serum Insititute of India is now the largest manufacturer of the vaccine in the world - projected to be in the billions of doses this year.The EU is now looking at UK plant to make up a shortfall in the EU’s production, based on some loose wording in the original Terms of Supply from August 2020. The UK are not blocking any exports of either vaccines or precursors, but are simply sticking to their May 2020 contract with AZ which demands the first 100 million doses of the Oxford vaccine produced by the UK plant being for UK consumption.The EU is demanding that AstraZeneca break its contract with the UK so that it can take advantage of the fact that UK production is working as it should, while EU production is still beset with delays.UK production is currently sufficient to meet the UK need for first and second doses, but no more. There is no ‘spare’ to supply the EU with until this bad boy comes online in the autumn:-The VMIC will have a capacity of around 140 million doses a year and will truly revolutionize vaccine development and production in the UK, which, with the addition of further fill-and-finish facilities, will make us truly self-sufficient in vaccine production, of all types, and able to vaccinate the entire UK population every six months just from local production.